MedTrace Logo

Ketorolac in Acute Pancreatitis

NCT04282200 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-12-08

No results posted yet for this study

Summary

This study will compare pain management strategies for patients hospitalized with acute pancreatitis. Standard of care pain management will be compared to standard of care plus intravenous ketorolac.

Conditions

Interventions

DRUG

Ketorolac

intravenous ketorolac 30 mg every 6 hours

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Anthony J Gentene, PharmD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2021-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04282200 on ClinicalTrials.gov